A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone Deficiency
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This study investigates the safety, tolerability, pharmacokinetic profile (PK), and
pharmacodynamic response (PD) of three different doses of ACP-001 given once-a-week compared
to one dose-level of an approved daily human growth hormone product over a period of 4 weeks
(4 weekly administrations versus 28 daily administrations) in adults with Growth Hormone
Deficiency.